Jefferies downgraded Opko Health (OPK) to Hold from Buy with a price target of $1.60, down from $2. The firm, which is lowering Ngenla out-year estimates, says Opko’s drug pipeline has potential, but is still early with a need for clarity on catalysts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPK: